With more than 30 years in the biopharmaceutical industry, Mr. Turgeon has significant experience in business operations and sales across multiple areas, including oncology, inflammation and bone health. He has held several senior leadership positions at Spectrum and at Amgen. Mr. Turgeon holds a Bachelor of Science degree from Jacksonville University, where he studied microbiology and economics.
Thomas Riga Chief Operating Officer
With more than 20 years of experience in biopharmaceuticals, Mr. Riga has significant experience leading teams in manufacturing, sales, marketing, six sigma business development and operations. Mr. Riga has held several senior leadership roles at Spectrum, as well as various leadership positions at Wyeth Ayerst, Eli Lilly, Amgen and Dendreon. Mr. Riga has Bachelor of Science degree from St. Lawrence University, where he studied biology and chemistry.
Kurt Gustafson Chief Financial Officer
Mr. Gustafson has more than 25 years of diverse experience in corporate finance, with 15 years in senior management roles leading the finance departments of multi-faceted, dynamic and growth-oriented biopharmaceutical industry organizations. He has held senior leadership positions at Halozyme Therapeutics and Amgen and currently serves on the board of directors of Xencor and Chromadex. Kurt received his BA in Accounting from North Park University and his MBA from the UCLA Anderson School of Management.
Keith McGahan Chief Legal Officer
With more than 15 years in the healthcare industry, Mr. McGahan has significant experience in compliance and regulation, risk mitigation, policies and procedures, and general counsel. Mr. McGahan has held several senior leadership positions at other healthcare corporations, including Avanir Pharmaceuticals and Johnson & Johnson. He also served as the U.S. Navy Judge Advocate General (JAG). Mr. McGahan received his Master in Laws in Taxation from the University of San Diego School of Law and a Juris Doctorate degree from Seattle University.
Francois Lebel, MD, F.R.C.P.C. Chief Medical Officer
With nearly 30 years in the biopharmaceutical industry, Dr. Lebel has broad and deep experience in oncology drug development, including risk management, global regulatory expertise, pharmacovigilance and medical affairs. Dr. Lebel has held several leadership positions in other biopharmaceutical companies, including ZIOPHARM Oncology, Baxter International, MedImmune and GSK. He received his medical degree from the University of Ottawa, Canada, and completed his post graduate training at McGill University and Harvard Medical School. Dr. Lebel is Board Certified in Internal Medicine and a fellow of the Royal College of Physicians of Canada.
Zane Yang, MD Vice President, Clinical Development
Dr. Yang joins Spectrum from Inovio Pharmaceuticals where he was Vice President, Clinical Development Oncology for Inovio's entire Oncology Therapeutic Area. He led Inovio's Clinical Development for all oncology immunotherapies and cancer vaccines, as well as all collaborative activities with external organizations. Prior to Inovio, he was Director of Medical Affairs and Clinical Development at Janssen, Novartis Oncology and Merck & Co.
Dr. Yang, who earned his M.D. at Beijing Medical University, was a fellow at Emory University's Winship Cancer Institute, University of Pennsylvania and the Wistar Institute in Philadelphia. Before transitioning to the pharmaceutical industry, he was associate professor at the University of Virginia Medical Center in Charlottesville, VA.
Michael A. Grabow Senior Vice President, Corporate Strategy & Operations
Michael Grabow is responsible for leading Spectrum’s Corporate Strategy & Operations function. This function is accountable to coordinate, operationalize, and align the organization on the core strengths needed for Spectrum to be successful in the future. Michael is responsible for driving Corporate Strategy and Operational Excellence throughout the organization and is also responsible for Spectrum’s Commercial Operations, Marketing, and National Accounts functions.
Michael has over 23 years of operations, commercial and finance related experience in multiple industries with 18 of these years being within the pharmaceutical industry. Since joining Spectrum in 2013, Michael has held roles with increasing levels of responsibility within the Commercial Organization. In addition, Michael was recently named 2017 Executive of the Year.
Michael holds a Bachelor of Science degree in Finance from California State University, Northridge and a Masters in Business Administration from Pepperdine University.
Guru Reddy, PhD Vice President, Preclinical Research & Development
Dr. Reddy has over 20 years of research and development management experience in the biotechnology industry and has a demonstrated track record of oncology drug development. He has diverse experience in preclinical research and development, early clinical development, regulatory strategy and IP strategy. He joined Spectrum in 2004 has taken increasing roles of responsibility. He is currently responsible for preclinical research and development and clinical pharmacology. At Spectrum, he has been part of four NDA submissions and three FDA approved products (FUSILEV, BELEODAQ and EVOMELA).
Prior to joining Spectrum, Dr. Reddy worked at Ciphergen Biosystems and Pangene Corporation. He was the scientific co-founder of Pangene Corporation and in charge of the oncology division of Pangene.
Dr. Reddy obtained his PhD in biochemistry from Poona University in India and post-doctoral training at Yale University. Dr. Reddy has published over 30 publications in peer reviewed journals and over 50 abstracts at international conferences. In addition, he is an inventor on 17 issued U.S. patents.
Ms. Retterson has more than 25 years of experience in the biopharmaceutical industry. She joined Spectrum in 2015, and is currently Vice President, Pharmaceuticals Operations. She is responsible for development and manufacturing of Spectrum’s products, such as the Rolontis® (eflapegrastim) and poziotinib programs, as well as insuring safety and quality, optimizing production and reducing manufacturing cost.
Over her career, Ms. Retterson has been responsible for the successful manufacture of several top biologics including: EPOGEN®, Neupogen®, Aranesp®, Neulasta®, Infergen®, Enbrel®, Cerazyme®, Fabrazyme ® and Myozyme®.
She has served as site head and general manager at Amgen, Genzyme and Charles River where she oversaw manufacturing, QA, QC, process development and supply chain. Most of her professional career was spent at Amgen, where she held a variety of positions of increasing responsibility including VP / GM of Amgen’s Rhode Island Facility and Site Head of Amgen’s multi-plant Thousand Oaks manufacturing site. During her tenure as GM at Charles River, she also had P&L responsibility for the site.
Ms. Retterson was a founding member of Amgen’s Sales and Marketing Department where she served as EPOGEN® product manager during the product’s first three years, and where she led the team that secured the first-ever Medicare reimbursement for a biologic. She also served as Controller for Amgen’s operations and capital investments groups for two years.
Ms. Retterson holds a BA in American History with Honors from Brown University and an MBA from Stanford University.
Shiv Kapoor Vice President, Strategic Planning and Investor Relations
Mr. Kapoor has more than 20 years of experience in finance, investments, research, and regulatory primarily in the Biotechnology sector. Prior to joining Spectrum, he had a Wall Street career both as a Sell Side analyst at various investment banks, most recently as a Managing Director at Morgan Joseph, and as an investor, most recently as a Portfolio Manager at Citigroup. Previously, Mr. Kapoor held research, business development and regulatory roles at Johnson & Johnson, Guidant, and Alza Corporation. He also has been an early stage investor in several startups including LegalZoom, Infinera Corp, and Dilithium technologies.
Mr. Kapoor holds a B.A. in Molecular Cell Biology from University of California, Berkeley and an MBA focused in Strategy, Finance and Entrepreneurship where he studied microbiology and economics.
Bimal R. Shah Vice President, Corporate and Business Development
Mr. Shah has approximately 20 years of experience in corporate and business development, finance, and investments, primarily focused on the pharmaceutical and biotechnology sector. Previous to his current role at Spectrum, he served as Vice President of Finance and Business Development at Spectrum. Prior to joining Spectrum, he had a career at multiple financial institutions including Warburg Pincus, J.P. Morgan and Goldman Sachs, where his activities were concentrated on investing in and advising companies in the healthcare industry, particularly life sciences. Mr. Shah has also held roles in market development and business development at Genentech. In addition to his full-time roles, he has served as an advisor and consultant to multiple private and public companies.
Mr. Shah holds a B.A. in Economics, M.A. in International Policy Studies and MBA, all from Stanford University.